News & Updates

The selective β3-AR agonist mirabegron appears to confer benefits for both overactive bladder (OAB) symptoms and erectile dysfunction (ED) in some patients without compromising safety, as reported in a study.

Young men with type D personality (TDP) have a higher prevalence of erectile dysfunction (ED), according to a Taiwan study.

Men with Trichomoniasis vaginalis infections appear to be at an elevated risk of prostate cancer (PCa) and benign prostate hyperplasia (BPH), according to a recent study.

The presence of erectile dysfunction (ED) does not appear to confer an increased risk of cardiovascular disease (CVD) and mortality in men with diabetes mellitus (DM), with comparable risk of adverse cardiovascular events among users and nonusers of phosphodiesterase-5 inhibitors (PDE5-Is), which are used to manage ED, according to a study.

Among prostate cancer patients aged ≥75 years, maximal androgen blockage (MAB) appears to be the most common treatment option, reports a new South Korea study. Meanwhile, the combination of leuprolide and bicalutamide is the most common MAB regimen.

In patients with intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), intravesical chemohyperthermia (CHT) does not translate to better cancer control than standard room-temperature chemotherapy, according to a recent phase II study HIVEC-II.

A recent first-in-human study has shown that directly applying pembrolizumab to the bladder is a safe and effective treatment option for patients with nonmuscle-invasive bladder cancer (NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG) treatment.